PITTSBORO, NC -- (MARKET WIRE) -- May 03, 2007 -- Biolex Therapeutics today announced that its LEX System(SM) technology for enabling hard-to-make proteins and optimizing monoclonal antibodies will be featured at the “Prevention and Cure: Contributions of Plant Biotechnology to Human Health” session at the 2007 BIO International Convention. David Spencer, Ph.D., Biolex’s Chief Operating Officer and Senior Vice President, Research and Development, will highlight the ability of the Company’s LEX System to increase the efficacy and potency of monoclonal antibodies and to enable the development and commercialization of new therapeutic proteins not well expressed in other systems. The session will take place at 4:00 p.m. EDT on Monday, May 7th at the Boston Convention & Exhibition Center in Room 253 B.
